Muscle Invasive Urothelial Carcinoma
Advertisement
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Data from 458 patients who underwent RC between October 2005 and October 2020 and 146 in the PURE-01 trial was analyzed.
Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab.
Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC.
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Patients with MIBC who are ineligible for cisplatin-based chemotherapy have no current standard of care options.
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Investigators used mixture cure models to estimate patients' underlying cure fraction after radical resection.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Dr. Li highlights the EFS data and interesting findings among patients with residual disease in the bladder or lymph nodes.
Dr. Li describes his recent study comparing neoadjuvant pembro vs chemo or upfront cystectomy in patients with MIBC.
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
The study summarized findings including the secondary end points of overall survival and time to death due to bladder cancer.
A combination of current guidelines and RCTs give surgeons clarity on the benefit of extended PLND in bladder cancer.
Physicians have yet to confirm the exact health needs of patients with MIBC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.